Outcomes of Transcatheter Edge‐to‐Edge Repair in Potentially Favorable Candidates for Left Ventricular Assist Device: Evidence From the OCEAN‐Mitral Registry
Journal of the American Heart Association 2026 Open access
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT
Free to try with your Science Catalogs account.
Abstract
Background Transcatheter edge‐to‐edge repair of the mitral valve (M‐TEER) has shown promising outcomes in patients with advanced heart failure and significant mitral regurgitation. Similarly, outcomes after left ventricular assist device (LVAD) implantation have improved in advanced heart failure with/without mitral regurgitation. However, the indication of M‐TEER in favorable candidates for LVAD therapy remains unclear. Methods Potentially favorable LVAD candidates were defined as patients with advanced heart failure and secondary mitral regurgitation who underwent M‐TEER and were considered theoretically suitable for LVAD therapy based on data from the optimized catheter valvular intervention (OCEAN)‐Mitral registry. Among this cohort, Cox proportional hazards regression analysis was performed to identify factors associated with cardiovascular death following M‐TEER. Results A total of 3764 patients who underwent M‐TEER were included. Of them, 129 were identified as potentially favorable LVAD candidates (mean age: 67 years; 67% men). Despite advanced heart failure, procedural success was 96%. The 1‐year rate of cardiovascular death was 10.1%, increasing to 38.9% at 3 years. Baseline left ventricular end‐diastolic diameter was independently associated with cardiovascular death (hazard ratio: 1.07 per 1‐mm increase; 95% CI: 1.02–1.12; P =0.01). In patients with markedly enlarged left ventricles, symptom improvement was limited, and reverse remodeling was not achieved. Conclusions M‐TEER can be safely performed even in potentially favorable LVAD candidates. However, long‐term efficacy appears limited, particularly in those with advanced LV remodeling. Further studies are warranted to establish an optimal strategy, including the role of LVAD therapy versus M‐TEER, for this high‐risk population. Registration URL: https://center6.umin.ac.jp/cgi‐open‐bin/ctr/ctr_view.cgi?recptno=R000027188 .
Fields of Study & Subjects
Cardiac Valve Diseases and Treatments
Mechanical Circulatory Support Devices
Cardiac Structural Anomalies and Repair
Publication details
- Journal / source
- Journal of the American Heart Association
- Volume
- 15
- Issue
- 7
- Pages
- e046638–e046638
- Publication date
- 25 March 2026
- Language
- EN